Cancer Prevention and Control Program (CPCP)

癌症预防与控制程序：摘要 亚利桑那大学癌症中心癌症预防与控制计划(CPCP) 进行高度互动、跨学科的癌症预防和控制研究，以减少癌症 负担。CPCP继续高度重视与集水区相关的癌症研究，以提供信息并产生影响 UACC集水区。具体目标是：(1)促进对癌症的了解和早期发现 通过识别危险因素以及检测生物标志物和成像技术的发展 (2)评估新的癌症防治剂和减轻癌症负担的策略 (干预)；和(3)实施以证据为基础的行为、心理和系统层面的战略，以 促进健康和改善成果(传播和实施)。CPCP成员已经做出了 癌症预防和控制研究在以下方面取得重大进展：(1)展示 消防员接触致癌物质会改变他们的DNA甲基化模式，从而导致政策的变化； (2)确定了西班牙裔和非西班牙裔白人肾癌的驱动因素的差异；(3)发展了一种 新的高灵敏度乳腺CT成像系统和智能手机共焦显微镜；(4)显示 西兰花种子提取物对烟草致癌物的解毒作用；(5)完成HPV疫苗接种 了解世界卫生组织全球疫苗接种指南政策的研究；(6)开发了一种高效的 支持拉丁裔乳腺癌幸存者和照顾者的症状管理方案；和(7) 将美国印第安人的癌症筛查率从9%提高到19%。CPCP有一种同行评议的癌症 集中资金基数为890万美元(直接成本)，其中600万美元(67%)来自国家癌症研究所(NCI)， 210万美元(24%)来自其他国家卫生研究院，80万美元(9%)来自其他同行审查 消息来源。值得注意的是，CPCP的NCI资金比上一报告期报告的资金高出50%。 在本报告所述期间，CPCP成员在33项与癌症相关的同行审查的多项PI中获得了4700万美元 资助金。这些MPI包括12个R01、2个P01、1个U54，以及与66个机构的合作伙伴关系 国家，其中三个是NCI指定的癌症中心。基金包括皮肤癌的新P01 预防；新的UG1赠款用于领导癌症预防药物的早期临床试验，这是仅有的五种药物之一 NCI资助的计划；新的疾病控制和预防中心癌症资助作为亚利桑那州的网站 国家癌症预防临床试验网络；和P42资金，以解决矿山废物暴露和 癌症宣传。在本项目期间，CPCP成员编写了525个与癌症相关的 出版物，其中122份(23%)是方案内出版物，76份(14%)是方案间出版物，311份(59%)是方案间出版物 跨机构的。此外，CPCP成员申请了59项专利，其中12项(20%)已获授权。在.期间 在项目期间，CPCP累积了8941名临床研究参与者，其中6496名累积到 由调查员发起的审判比上一时期增加了2倍。

CANCER PREVENTION & CONTROL PROGRAM: ABSTRACT The Cancer Prevention & Control Program (CPCP) at the University of Arizona Cancer Center (UACC) conducts highly interactive, transdisciplinary cancer prevention and control research to reduce the cancer burden. CPCP maintains a strong emphasis on catchment-relevant cancer research that informs and impacts the UACC Catchment Area. The Specific Aims are to: (1) advance understanding and early detection of cancer through identification of risk factors and development of detection biomarker and imaging technologies (Discovery); (2) evaluate novel cancer preventive agents and strategies to reduce the cancer burden (Intervention); and (3) implement evidence-based behavioral, psychosocial, and system-level strategies to promote health and improve outcomes (Dissemination and Implementation). CPCP Members have made significant progress on cancer prevention and control research in the following areas: (1) demonstrated exposure of firefighters to carcinogens that alter their DNA methylation patterns, leading to changes in policy; (2) identified differences in drivers of renal cancer in Hispanics versus non-Hispanic Whites; (3) developed a new highly sensitive breast-CT imaging system and smartphone confocal microscope; (4) showed that a broccoli seed extract upregulated detoxification of tobacco carcinogens; (5) completed HPV vaccine dosing studies that informed on WHO policy for worldwide vaccination guideline; (6) developed a highly effective symptom management program for support of Latina breast cancer survivors and caregivers; and (7) increased cancer screening rates in American Indians from 9% to 19%. CPCP has a peer-reviewed, cancer focused funding base of $8.9M (direct costs) of which $6M (67%) is from the National Cancer Institute (NCI), $2.1M (24%) from other National Institutes of Health sources, and $0.8M (9%) from other peer-reviewed sources. Of note, CPCP’s NCI funding is 50% higher than that reported during the prior reporting period. During the reporting period, CPCP Members were awarded $47M in 33 peer-reviewed cancer-relevant multi-PI grants. These MPIs included 12 R01s, two P01s, one U54, and partnerships with 66 institutions across the country, of which three were NCI-designated cancer centers. Funding includes a new P01 in skin cancer prevention; a new UG1 grant to lead early-phase clinical trials of cancer preventive agents, one of only five NCI-funded programs; new Centers for Disease Control and Prevention cancer funding as the Arizona site for the national Cancer Prevention Clinical Trials Network; and P42 funding to address mine waste exposures and cancer promotion. During the current project period, CPCP Members authored 525 cancer-relevant publications, of which 122 (23%) were intraprogrammatic, 76 (14%) were interprogrammatic, 311 (59%) were inter-institutional. In addition, CPCP members filed 59 patents, of which 12 (20%) were issued. During the project period, CPCP accrued 8,941 participants to clinical studies, 6,496 of which were accrued to investigator-initiated trials representing a 2-fold increase compared to the prior period.